OBRESOL

The rising incidence of obesity-related diseases poses a socio-challenge , requiring new therapeutic strategies. Among the comorbidities of obesity are metabolic and steatotic liver disease (MASLD) and breast cancer, conditions characterized by chronic, low- Degree. Inflammation resolution is an active process involving a series of pro-resolving lipid mediators (SPMs). These SPMs (such as lipoxins, resolvins, protectins, and maresins) are essential for resolving inflammation and promote tissue repair. Various programs of study have suggested that obesity is associated with a deficiency of SPMs and their precursors. Our hypothesis is that impaired SPM production underlies the chronic, low- Degree inflammation present in obesity and increases the risk of development and the progression of associated comorbidities such as MASLD and breast cancer. Therefore, it is essential to characterize both the alterations in SPM signatures associated with these diseases and the changes induced by therapeutic interventions, including dietary ones.

Therefore, the primary goal of the project is to evaluate, in a cohort of overweight/obese subjects with MASLD, changes in plasma SPM levels following dietary interventions. Analyzing the association of these levels with markers of response to per diem expenses and the progression of MASLD could reveal SPMs as effective lipidomic biomarkers for the development of precision nutrition strategies. Furthermore, in the context of breast cancer, we propose a study in a cohort of postmenopausal patients who are normal weight or overweight/obese, examining both the expression of SPM receptors and the enzymes involved in their training in the tumor microenvironment, as well as the levels of SPMs in the adipose tissue adjacent to the tumor. Analyzing the association s of these variables with tumor properties and the patients’ clinical characteristics may reveal their potential use as diagnostic biomarkers and as potential adjuvants to cancer treatments. In addition, we propose conducting a comparative study of the plasma lipidomic signature of SPMs in this cohort, comparing women of normal weight and those who are overweight or obese—with and without breast cancer—as well as studying changes in SPM levels one year after diagnosis in patients with breast cancer. assessment , the association of these levels with markers of cardiometabolic health and patients’ quality of life could indicate a potential use as a biomarker for diagnosis and disease progression. In summary, the results obtained may reveal the utility of SPMs as biomarkers for diagnosis, prognosis, and response to per diem expenses in MASLD and breast cancer, thereby contributing to the design of effective therapeutic strategies for these conditions.